April 28, 2025 10:59 AM EDT

Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe

ENDPOINTS

Plus, #AUA2025 news from Protara Therapeutics, Pfizer, CG Oncology, and UroGen, in addition to the latest updates from Spruce Biosciences and Rezolute:

Biohaven’s up to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe

ENDPOINTS

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Boehringer’s updated results in HER2-mutated lung cancer impress

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

Revolution Medicines' KRAS drug shows potential in early cut of lung cancer data

Exclusive: Can AI replace animal testing? A new biotech launches to find out

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Bio­haven gets an up to $600M in­vest­ment; Prile­nia, Fer­rer make a deal in Eu­rope

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe